Search

After a Speedy IPO, Equillium Expands Antibody R&D to Renal Disease

AFTER A SPEEDY IPO, EQUILLIUM EXPANDS ANTIBODY R&D TO RENAL DISEASE

Equillium, a biotech that's looking to develop an antibody drug for immuno-inflammatory diseases, has added a form of renal disease...